02:12 , Dec 1, 2018 |  BioCentury  |  Politics, Policy & Law

China’s germline growing pain

How Chinese regulatory authorities respond over the long term to the CRISPR baby furor could influence its industry’s success on the global stage, as domestic and international stakeholders seek reassurance that the authorities are on...
17:27 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Sensitivity of Berry Genomics' early HCC screen exceeds 90%

Berry Genomics Co. Ltd. (SZSE:000710) said its PreCar next-generation sequencing-based liver cancer risk prediction model detected early hepatocellular carcinoma with >90% sensitivity at 95% specificity in a pilot trial. At 99% specificity, the model detected...
21:41 , Sep 24, 2018 |  BC Extra  |  Clinical News

Sensitivity of Berry Genomics' early HCC screen exceeds 90%

Berry Genomics Co. Ltd. (SZSE:000710) said its PreCar next-generation sequencing-based liver cancer risk prediction model detected early hepatocellular carcinoma with >90% sensitivity at 95% specificity in a pilot trial. At 99% specificity, the model detected...
03:53 , Sep 21, 2018 |  BC Innovations  |  Product R&D

China’s rising genomics start-ups

Behind bellwethers BGI Genomics Co. Ltd. and WuXi NextCode Genomics Inc., a new generation of Chinese genomics companies is emerging with ambitions to solve urgent problems, including early cancer detection and clinical trial recruitment, by...
20:39 , Sep 8, 2017 |  BC Week In Review  |  Company News

Berry Genomics completes reverse merger

Gene sequencing company Berry Genomics Co. Ltd (SZSE:000710) completed a reverse merger on Aug. 10 with auto parts company Chengdu Tianxing Instrument & Meter Co. Tianxing will retain a 12.4% stake in the company (see...
00:38 , Dec 31, 2016 |  BioCentury  |  Finance

Public shortcut

Berry Genomics Co. Ltd. hopes to cut its path to a public listing in half by opting for a reverse merger rather than an IPO. According to a Dec. 4 regulatory filing, Berry plans to...
21:58 , Dec 30, 2016 |  BC Week In Review  |  Company News

Berry, Tianxing deal

Berry Genomics will reverse-merge with auto parts company Tianxing Instrument to form a publicly traded gene sequencing company. According to a regulatory filing, the deal values Berry at RMB4.3 billion ($618.8 million). Berry Genomics provides...
00:09 , Dec 30, 2016 |  BC Extra  |  Financial News

Berry Genomics pursues listing via reverse merger

Berry Genomics Co. Ltd. (Beijing, China) will reverse-merge with auto parts company Chengdu Tianxing Instrument & Meter Co. (SZSE:000710) to form a publicly traded gene sequencing company on the Shenzhen Stock Exchange, according to a...
18:20 , Nov 18, 2016 |  BioCentury  |  Finance

Currency options

Less than a year after raising a super-sized U.S. dollar fund, Qiming Venture Partners is back with a new Chinese-focused fund in renminbi. Qiming says the investment strategies are the same, but that having both...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Company News

BioNano Genomics, Berry Genomics deal

BioNano and Berry partnered to co-develop a next-generation genomic mapping system in China. The companies will use assays designed by the partners and a next-generation mapping system based on BioNano’s Irys platform to develop assays...